Core Research

Metabolism Comparison Matrix

“Metabolic & NAD+ Research” is a catalogue grouping, not a single biochemical mechanism. The category contains a dinucleotide cofactor, peptides, a small-molecule enzyme inhibitor, a carnitine solution and a growth-hormone fragment analogue. The correct material depends on the experimental question.

Metabolism research matrix

MaterialEntity classRepresentative research questionMain evidence caution
NAD+ 1000mgDinucleotide cofactorRedox chemistry and NAD-consuming enzymes such as sirtuins, PARPs and CD38Do not convert pathway association into an anti-ageing or energy claim
MOTS-c 40mgMitochondria-derived peptide research entityMetabolic signalling and stress-response pathwaysExact peptide form and preclinical model matter
SS-31 10mgMitochondria-targeting tetrapeptide research entityCardiolipin/membrane biophysics and mitochondrial protein interactionsDo not equate RUO material with a regulated elamipretide medicine
5-Amino-1MQ 50mgSmall-molecule NNMT inhibitor research compoundNNMT-related metabolic flux in experimental modelsAnimal weight/metabolic endpoints are not a consumer outcome claim
L-Carnitine 600mg/mlSmall zwitterionic carnitine compound in a finished liquid formulationCarnitine shuttle and long-chain fatty-acid transportFinished-solution concentration/formulation evidence is product-specific
AOD9604 5mgSynthetic hGH-fragment-related peptide research entityRodent metabolic and beta-adrenergic-signalling questionsRodent body-weight/fat findings do not establish human weight management

NAD+ is a biochemical cofactor, not a peptide

NAD+ participates in redox reactions and is consumed by several signalling-enzyme families. Its experimental handling and assay design therefore differ fundamentally from peptide products. See the NAD+ research overview.

MOTS-c and SS-31 ask different mitochondrial questions

MOTS-c literature focuses on mitochondria-derived peptide signalling and metabolic responses. SS-31 research focuses strongly on cardiolipin-rich membranes, membrane biophysics and mitochondrial protein interactions. Grouping them under “mitochondrial research” does not make their mechanisms or assay designs interchangeable.

5-Amino-1MQ and L-carnitine are not peptides

5-Amino-1MQ is studied as a small-molecule NNMT inhibitor. L-carnitine is part of the carnitine shuttle used for long-chain acyl-group transport. Their chemical identity, formulation and analytical methods differ from peptide workflows.

The analytical package also changes with the entity. NAD+/NADH redox-state assays, peptide sequence and mass assignments, small-molecule inhibitor characterisation, and a finished L-carnitine solution’s concentration/formulation are different measurement tasks. A chromatographic area percentage, identity spectrum or nominal label on one class should not be treated as equivalent to quantitative content or product-lot verification for another class. Use the method and units actually reported for the material in question, with the CoA-reading guide as a documentation framework.

AOD9604 belongs to a different evidence family

AOD9604 is a growth-hormone-fragment-related peptide studied in rodent metabolic models. Its category position does not make it a NAD-pathway compound or a substitute for the other entries.

How to select an experimental material

  1. Define the molecular process: redox cofactor, mitochondrial membrane, peptide signalling, enzyme inhibition or fatty-acid transport.
  2. Choose the material whose literature actually addresses that process.
  3. State the exact entity/form and model.
  4. Use product documentation for formulation and lot-specific evidence.
  5. Keep animal and cell endpoints separate from human outcome claims.

Research-use boundary

This matrix does not rank compounds for fat loss, anti-ageing, exercise performance, metabolic health or safety. It provides laboratory-research disambiguation only.